Title: Biosafety risk assessment of the severe acute respiratory syndrome (SARS) Coronavirus and containment measures for the diagnostic and research laboratories
Authors: Herman, P ×
Verlinden, Y
Breyer, D
Van Cleemput, E
Brochier, B
Sneyers, M
Snacken, René
Hermans, P
Kerkhofs, P
Liesnard, Corinne
Rombaut, B
Van Ranst, Marc
Van der Groen, Guido
Goubau, Patrick
Moens, W #
Issue Date: 2004
Publisher: American Biological Safety Association
Series Title: Applied Biosafety vol:9 issue:3 pages:128-142
Abstract: At the end of 2002, an outbreak of a new viral respiratory illness, called SARS (Severe Acute Respiratory Syndrome virus), occurred in China. The disease spread over Asia, North America, Europe and Africa. In response to the SARS outbreak, the World Health Organization (WHO) coordinated an international collaboratorion that included clinical, epidemiologic, and laboratory investigations, and initiated efforts to control the spread of SARS. As in other countries, Belgium has been decided to establish biosafety guidelines and recommendations with particular emphasis on handling clinical specimens associated with SARS for research, production, and clinical laboratories. Taking into account that there is so far no SARS case reported in Belgium as well as in other countries in the world, and based on a scientific risk assessment related to the contained use of biological agents, the SARS-CoV was classified as a Risk Group 3 agent. In relation to the reported biosafety assessment, the SARS-CoV should be handled in appropriate biosafety containment levels to avoid laboratory-acquired infections and spread of the disease in the human population and the environment. Therefore, diagnostics activities with inactivated clinical specimens associated with SARS cases and with specimens originating in countries where SARS is documented but associated with SARS cases should be performed under Biosafety Level 2 (BSL-2) conditions. Diagnostic activities involving non activated clinical specimens associated with SARS should be carried out under biosafety BSL-2 containment with BSL-3 safety equipment and work practices. Culture of SARS-CoV and all research activities involving SARS-CoV required a BSL-3 containment.
ISSN: 1535-6760
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Clinical and Epidemiological Virology (Rega Institute)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.